CN111973699A

CN111973699A - Chinese medicine compound preparation for treating coronary heart disease and angina pectoris by combining Chinese medicine and western medicine

Info

Publication number: CN111973699A
Application number: CN202010922059.1A
Authority: CN
Inventors: 李朝虹; 张宇明; 薛春香; 霍秉新; 刘全志
Original assignee: Inner Mongolia Tianheng Hospital Management Co ltd
Current assignee: Inner Mongolia Tianheng Hospital Management Co ltd
Priority date: 2020-09-04
Filing date: 2020-09-04
Publication date: 2020-11-24

Abstract

The embodiment of the invention discloses a Chinese herbal compound preparation for treating coronary heart disease and angina pectoris by combining Chinese medicines and western medicines, belonging to the technical field of Chinese medicines. The traditional Chinese medicine compound preparation is prepared from the following raw materials in percentage by weight: 11.1 percent of astragalus, 5.5 percent of safflower, 5.5 percent of peach kernel, 8.3 percent of salvia miltiorrhiza, 5.5 percent of sandalwood, 2.8 percent of szechuan lovage rhizome, 8.3 percent of red paeony root, 5.5 percent of Chinese angelica, 11.1 percent of kudzuvine root, 5.5 percent of earthworm, 5.5 percent of nutgrass galingale rhizome, 5.5 percent of snakegourd peel, 5.5 percent of corydalis tuber, 8.3 percent of stir-fried largehead atractylodes rhizome and 6.1 percent of Chinese yam, and the medicaments are compatible for removing blood stasis, relieving pain, tonifying deficiency and. The traditional Chinese medicine compound preparation disclosed by the invention is used for treating the coronary heart disease by combining with western medicines, dredging coronary artery vessels to the maximum extent, is remarkable in curative effect, can reduce the attack frequency of angina pectoris, shorten the attack time and relieve the angina pectoris, and has a clinical popularization value.

Description

Chinese medicine compound preparation for treating coronary heart disease and angina pectoris by combining Chinese medicine and western medicine

Technical Field

The embodiment of the invention relates to the technical field of traditional Chinese medicine compound preparations, in particular to a traditional Chinese medicine compound preparation for treating coronary heart disease and angina pectoris by combining traditional Chinese medicine and western medicine.

Background

Coronary heart disease is a common cardiovascular disease, and is caused by coronary atherosclerosis, blood vessel obstruction and stenosis, and further blood transportation is not smooth, so myocardial ischemia, hypoxia and necrosis are caused. The clinical manifestations are angina pectoris, severe cases even induce heart failure. Angina pectoris is the main accompanying symptom of coronary heart disease, and chest pain or chest discomfort is caused by temporary or acute ischemia or anoxia of cardiac muscle. Myocardial ischemia for a long time can also induce inflammation, so that the inner wall of an artery is damaged and broken, thrombus is caused, and acute myocardial infarction is generated. With the repeated attack and deterioration of the disease, patients are easy to have acute coronary syndrome, myocardial infarction and sudden cardiac death, thereby endangering life safety. Coronary heart disease and angina pectoris are common in the middle-aged and the elderly, and abnormal lipid metabolism, smoking, diabetes and hypertension are risk factors. According to statistics, about 60 million people die of coronary heart disease every year in China, and the life health of people is seriously threatened.

Western medicine usually takes nitrate medicine to relieve symptoms when angina pectoris attacks, and then carries out conventional treatments such as platelet aggregation resistance, lipid regulation and speckle stabilization, and the like, so that the traditional Chinese medicine can not be cured radically and has great side effects. If the disease condition is not controlled for a long time, the patient needs to be treated by a large-scale operation.

According to the traditional Chinese medicine, the coronary heart disease and angina pectoris are regarded as 'thoracic obstruction', and the development of the angina pectoris is mostly excess firstly and then deficiency, namely qi stagnation, blood stasis, qi deficiency and phlegm stagnation, and also has the symptoms of blood stasis, deficiency and excessive phlegm; blood stasis and phlegm coagulation are the main symptoms of coronary heart disease. The syndrome of deficient principal and excessive secondary aspect due to disharmony of yin and yang, deficiency of qi and blood and obstruction of qi and blood is caused by improper diet and fatigue. The disease position is in the heart, but the liver, heart, lung and spleen are all damaged, and the treatment principle of promoting blood circulation by removing blood stasis, eliminating phlegm and dredging collaterals is further provided. Although the clinical conventional western medicine treatment can relieve the symptoms to a certain extent, the side effect is large and the diseases cannot be cured radically. Based on this, the improvement of the disease by the combined treatment of Chinese and Western medicine is discussed.

Disclosure of Invention

Therefore, the embodiment of the invention provides a Chinese herbal compound preparation for treating coronary heart disease and angina pectoris by combining Chinese medicines and western medicines.

In order to achieve the above object, the embodiments of the present invention provide the following technical solutions:

a Chinese medicine compound preparation for treating coronary heart disease and angina pectoris by combining Chinese medicines and western medicines is prepared from the following medicinal materials in percentage by weight: 11.1% of astragalus, 5.5% of safflower, 5.5% of peach kernel, 8.3% of salvia miltiorrhiza, 5.5% of sandalwood, 2.8% of ligusticum wallichii, 8.3% of red paeony root, 5.5% of angelica, 11.1% of kudzu root, 5.5% of earthworm, 5.5% of rhizoma cyperi, 5.5% of pericarpium trichosanthis, 5.5% of rhizoma corydalis, 8.3% of fried bighead atractylodes rhizome and 6.1% of Chinese yam.

Furthermore, the traditional Chinese medicine compound preparation is a traditional Chinese medicine oral preparation.

Furthermore, the traditional Chinese medicine oral preparation is a decoction.

Further, the preparation method of the traditional Chinese medicine compound preparation comprises the following steps:

weighing radix astragali, Carthami flos, semen Persicae, Saviae Miltiorrhizae radix, lignum Santali albi, rhizoma Ligustici Chuanxiong, radix Paeoniae Rubra, radix Angelicae sinensis, radix Puerariae, Lumbricus, rhizoma Cyperi, pericarpium Trichosanthis, rhizoma corydalis, parched Atractylodis rhizoma and rhizoma Dioscoreae according to the component ratio, soaking in water for 3h, gradually heating to 100 deg.C, decocting for 40 min-1 hr, and filtering to obtain water decoction. Preferably, the corydalis tuber is pulverized into coarse powder.

The embodiment of the invention has the following advantages:

in the traditional Chinese medicine formula, the safflower, the peach kernel and the salvia miltiorrhiza are monarch drugs, and the safflower recorded in compendium of materia medica has the functions of promoting blood circulation and dredging channels, and removing blood stasis and relieving pain, and can treat chest stuffiness and pains, abdominal pain due to stasis and stabbing pain in chest and hypochondrium; peach kernel has the functions of promoting blood circulation and removing blood stasis; salvia miltiorrhiza, which is warm in nature and bitter in taste, has the effects of removing blood stasis, promoting blood circulation, promoting tissue regeneration and the like, and is commonly used for treating angina pectoris, hypertension, chest distress and other diseases. The red paeony root and the Szechuan lovage rhizome are ministerial drugs, the red paeony root is bitter in property and slightly cold, belongs to liver channels, and is used for promoting blood circulation, removing blood stasis and cooling blood; chuan Xiong is warm in nature and pungent in flavor, enters pericardium, liver and gallbladder meridians, has the effects of activating blood and qi, dispelling wind and relieving pain, and is mainly used for treating blood stasis and qi stagnation. The two medicines assist the monarch medicine to activate blood circulation, remove stasis and relieve pain. Sandalwood, rhizoma cyperi and rhizoma corydalis are also ministerial drugs, and the sandalwood has the effects of relieving chest stuffiness, regulating qi and relieving pain and is used for treating heart and abdomen pain and chest discomfort; the rhizoma cyperi has the effects of regulating qi, relieving depression, dredging collaterals and relieving pain; corydalis tuber has the functions of promoting blood circulation, removing blood stasis, regulating qi and relieving pain, and mainly treats various pains of heart, abdomen, waist and knees. The medicines are used together to assist monarch medicines in removing blood stasis, regulating qi and relieving pain, thereby relieving angina. Astragalus root, kudzuvine root, white atractylodes rhizome, Chinese angelica, Chinese yam and snakegourd peel are adjuvant drugs, coronary heart disease is chronic disease, hypertension, diabetes and the like mostly take two decades to develop into the coronary heart disease, and deficiency is caused by long-term disease, so most of the patients have the symptoms of deficiency of qi and deficiency of yin and blood, and the astragalus root, the Chinese angelica and the kudzuvine root are used for tonifying qi, nourishing blood and nourishing yin. Bighead atractylodes rhizome, rhizoma Atractylodis Macrocephalae, strengthens the spleen and eliminates phlegm, trichosanthes peel, fructus trichosanthis, radix trichosanthis, cortex trichosanthis, phlegm removing and nodulation dissipating, is used for assisting with various medicines to play a therapeutic role. Earthworm is a guiding drug and can dredge collaterals and remove arthralgia. Earthworm is easy to drill, has the effect of dredging channels and collaterals, and can guide medicine to all parts of blood vessels to achieve the effect of dredging the whole body blood vessels. The modern pharmacy uses lumbrokinase extracted from lumbricus for thrombolytic therapy, and can effectively dissolve thrombus, improve microcirculation, strengthen collateral circulation of heart and cerebral vessels, reduce blood viscosity, reduce platelet aggregation rate, and inhibit thrombosis. The medicines are compatible for removing blood stasis, relieving pain, tonifying deficiency and eliminating phlegm, so as to achieve the effects of promoting blood circulation, removing blood stasis, resolving masses and relieving pain, and the principal and secondary aspects are treated simultaneously after long-term administration.

Coronary heart disease and angina pectoris are mainly caused by atherosclerotic plaque growing in coronary artery supplying blood to heart, which causes myocardial blood supply insufficiency, and the plaque of blood vessel is removed to dredge blood vessel in order to treat radically. The traditional Chinese medicine compound preparation disclosed by the invention is used for treating the coronary heart disease by combining with western medicines, dredging coronary artery vessels to the maximum extent, is remarkable in curative effect, can reduce the attack frequency of angina pectoris, shorten the attack time and relieve the angina pectoris, and has a clinical popularization value.

Detailed Description

The present invention is described in terms of particular embodiments, other advantages and features of the invention will become apparent to those skilled in the art from the following disclosure, and it is to be understood that the described embodiments are merely exemplary of the invention and that it is not intended to limit the invention to the particular embodiments disclosed. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention. The percentages in the following examples are by weight unless otherwise specified.

Examples

Weighing 20 g of astragalus membranaceus, 10 g of safflower, 10 g of peach kernel, 15 g of salvia miltiorrhiza, 10 g of sandalwood, 5 g of ligusticum wallichii, 15 g of radix paeoniae rubra, 15 g of angelica, 20 g of radix puerariae, 10 g of earthworm, 10 g of rhizoma cyperi, 10 g of pericarpium trichosanthis, 10 g of rhizoma corydalis (crushed into coarse powder), 15 g of fried rhizoma atractylodis macrocephalae and 11 g of Chinese yam, adding 0.8 l of water, soaking for 3h, putting into a closed decoction pot, decocting, gradually heating to 100 ℃, starting timing, continuing to decoct for 40 min, and filtering to obtain 440 ml of water decoction. The liquid medicine is extruded into a packaging machine for packaging, wherein each bag is 220 ml, and each dose is packaged into 2 bags.

Test examples

In order to illustrate the efficacy of the combination of Chinese and western medicines in treating coronary heart disease and angina pectoris, the present invention has been tested as follows.

1 data and method

1.1 general data

Patients with coronary heart disease and angina pectoris (n is 320) who are treated in 2016 from 1 month to 2019 from 4 months are randomly divided into two groups according to the treatment order. Control (n 160): 73/87 cases for male/female; the age is 30-87 years, and the average (61.91 +/-10.52) years; the disease course is 1-5 years, and the average (2.58 +/-1.08) years. Observation group (n 160): 88/72 cases for male/female; age 30-83 years, mean (61.61 ± 9.21) years; the course of disease is 1-4 years, and the average (2.39 +/-0.95) years. The demographic data of the two groups are compared, and the two groups have no obvious difference (p is more than 0.05) and are comparable.

And (3) inclusion standard: the Chinese medicinal preparation accords with coronary heart disease and angina pectoris diagnosis standards in Chinese chronic stable angina pectoris diagnosis and treatment guide and modern Chinese medicine clinical diagnostics; ② clear consciousness and no mental disorder; and voluntarily signing an informed consent.

Exclusion criteria: the compliance is poor, and the test cannot be completed cooperatively; blood coagulation and abnormal liver and kidney functions; ③ those with medication contraindications; fourthly, pregnant women and women in lactation period.

1.2 methods

[ CONTROL ] conventional western medicine treatment: rosuvastatin calcium tablet (jinuo) [ zhejiang jing new drug industry gmbh, national drug standard H20080483, specification: 10mg ], 1 tablet/time, 1 time/d; isosorbide mononitrate tablet (Xinkang) [ luminal fibrate pharmaceuticals ltd, national standard H10940039, specification: 20mg ], 1 tablet/time, 2 times/d; aspirin enteric coated tablet (bazaspirin) [ bayer medicine health care llc, national drug standard HJ20171021, specification: 100mg, 1 time/d, 1 tablet/time ], according to the instruction, the medicine is taken, and the treatment course is 12 weeks.

[ Observation group ] combined with traditional Chinese medicine treatment on the basis of a control group: the decoction of example 1 is administered once a day in the morning and evening. The treatment course is 12 weeks.

1.3 Observation index

The angina symptoms (number of attacks, duration of angina, degree of pain) score and clinical efficacy were observed in both groups of patients after 12 weeks of treatment. The therapeutic effect judgment standard is as follows: the effect is shown: the chest distress, chest pain and palpitation of the patient basically disappear; the method has the following advantages: the symptoms of chest distress and chest pain are obviously improved; and (4) invalidation: the symptoms are not obviously improved or aggravated. The total effective rate is (number of effective cases + number of effective cases)/the total number of cases × 100%.

1.4 statistical processing

Processing data by SPSS21.0 statistical software, expressing the measured data as (x +/-s), and testing by t; the data of counts are expressed in (%) as chi²Inspection of p<0.05 indicates that the difference is statistically significant.

Results

2.1 symptoms of angina pectoris

After treatment, the number of angina pectoris attacks of the patients in the observation group is obviously less than that of the patients in the control group, the duration is obviously shorter than that of the patients in the control group, the pain scores are obviously lower than that of the patients in the control group, and the differences have statistical significance (p is less than 0.05), which is shown in table 1.

Table 1: comparison of angina pectoris symptom scores before and after treatment (x + -s)

2.2 clinical efficacy

110 patients in the control group are effectively treated, wherein 80 patients are effectively treated, 30 patients are effectively treated, the effective rate is 50%, and the total effective rate is 68.75%; 154 patients in the observation group are effectively treated, wherein 141 patients have obvious effect, 13 patients have effective effect, the obvious effect rate is 88.12%, and the total effective rate is 96.25%. The total effective rate of the patients in the observation group is obviously higher than that of the patients in the control group, and the difference has statistical significance (P is less than 0.01), which is shown in table 2.

Table 2: clinical efficacy comparison of two groups of patients [ n (%) ]

In conclusion, the coronary heart disease and angina pectoris has obvious curative effect by adopting the combination of Chinese and Western medicines, can reduce the attack frequency of the angina pectoris, shorten the attack time and relieve the angina pectoris, and is recommended to be used conventionally.

Although the invention has been described in detail above with reference to a general description and specific examples, it will be apparent to one skilled in the art that modifications or improvements may be made thereto based on the invention. Accordingly, such modifications and improvements are intended to be within the scope of the invention as claimed.

Claims

1. A traditional Chinese medicine compound preparation for treating coronary heart disease and angina pectoris by combining traditional Chinese medicine and western medicine is characterized by being prepared from the following medicinal materials in percentage by weight: 11.1% of astragalus, 5.5% of safflower, 5.5% of peach kernel, 8.3% of salvia miltiorrhiza, 5.5% of sandalwood, 2.8% of ligusticum wallichii, 8.3% of red paeony root, 5.5% of angelica, 11.1% of kudzu root, 5.5% of earthworm, 5.5% of rhizoma cyperi, 5.5% of pericarpium trichosanthis, 5.5% of rhizoma corydalis, 8.3% of fried bighead atractylodes rhizome and 6.1% of Chinese yam.

2. The compound traditional Chinese medicine preparation for treating coronary heart disease and angina pectoris according to claim 1, wherein the compound traditional Chinese medicine preparation is an oral traditional Chinese medicine preparation.

3. The compound traditional Chinese medicine preparation for treating coronary heart disease and angina pectoris according to claim 2, wherein the oral traditional Chinese medicine preparation is a decoction.

4. The compound traditional Chinese medicine preparation for treating coronary heart disease and angina pectoris according to claim 1, wherein the preparation method of the compound traditional Chinese medicine preparation comprises:

weighing radix astragali, Carthami flos, semen Persicae, Saviae Miltiorrhizae radix, lignum Santali albi, rhizoma Ligustici Chuanxiong, radix Paeoniae Rubra, radix Angelicae sinensis, radix Puerariae, Lumbricus, rhizoma Cyperi, pericarpium Trichosanthis, rhizoma corydalis, parched Atractylodis rhizoma and rhizoma Dioscoreae according to the component ratio, soaking in water for 3h, gradually heating to 100 deg.C, decocting for 40 min-1 hr, and filtering to obtain water decoction.